Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
暂无分享,去创建一个
R. Kurzrock | J. Cortes | A. Tsimberidou | C. Bueso-Ramos | F. Giles | I. Khouri | S. Pilat | D. Thomas | C. Bueso‐Ramos
[1] G. Nucifora,et al. Targeted therapies in myelodysplastic syndromes: ASH 2003 review. , 2004, Seminars in hematology.
[2] R. Kurzrock,et al. Sequential interleukin 3 and granulocyte‐macrophage–colony stimulating factor therapy in patients with bone marrow failure with long‐term follow‐up of responses , 2003, Cancer.
[3] Augustin Ferrant,et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. , 2003, The New England journal of medicine.
[4] F. Zwaan,et al. Recombinant human interleukin 11 and bacterial infection in patients with haemological malignant disease undergoing chemotherapy: a double-blind placebo-controlled randomised trial , 2003, The Lancet.
[5] K. Momose,et al. Effects of Interleukin-11 on the Hematopoietic Action of Granulocyte Colony-stimulating Factor , 2002, Arzneimittelforschung.
[6] T. Horie,et al. Spontaneous clinical and cytogenetic remission of aplastic anemia in a patient with del(13q). , 2002, Cancer genetics and cytogenetics.
[7] P. Thall,et al. Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside. , 2002, Blood.
[8] C. Porta,et al. Recombinant human interleukin-11 (Neumega, rhIL-11) reduces thrombocytopenia in breast cancer patients receiving tandem autologous circulating progenitor cell transplantation , 2002, Annals of Hematology.
[9] J. Holland,et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] R. Kurzrock,et al. Pilot study of low-dose interleukin-11 in patients with bone marrow failure. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] J. Bussel,et al. A pilot study of rhuIL‐11 treatment of refractory ITP , 2001, American journal of hematology.
[12] B. Cheson,et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. , 2000, Blood.
[13] Gordon Ms. Advances in supportive care of myelodysplastic syndromes. , 1999 .
[14] N. Robert,et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. , 1997, Journal of Clinical Oncology.
[15] A. List,et al. Stimulation of hematopoiesis by amifostine in patients with myelodysplastic syndrome. , 1997, Blood.
[16] D. Williams,et al. Interleukin-11: review of molecular, cell biology, and clinical use. , 1997, Blood.
[17] S. Asano,et al. Treatment of the anemia of aplastic anemia patients with recombinant human erythropoietin in combination with granulocyte colony ‐ stimulating factor: a multicenter randomized controlled study , 1997, European journal of haematology.
[18] A. Ohsaka,et al. Sustained trilineage recovery and disappearance of abnormal chromosome clone in a patient with myelodysplastic syndrome following combination therapy with cytokines (granulocyte colony‐stimulating factor and erythropoietin) and high‐dose methylprednisolone , 1996, British journal of haematology.
[19] J. Perkins,et al. The platelet-refractory bone marrow transplant patient: prophylaxis and treatment of bleeding. , 1993, Seminars in oncology.
[20] M. Mittelman,et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. , 1992, Blood.
[21] R. Kurzrock,et al. Very low doses of GM-CSF administered alone or with erythropoietin in aplastic anemia. , 1992, The American journal of medicine.
[22] H. Gerhartz,et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia , 1992, Annals of Hematology.
[23] H. Gerhartz,et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia , 1992, Annals of Hematology.
[24] R. Abels,et al. Pharmacologic doses of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. , 1991, Blood.
[25] Z. Estrov,et al. Phase I study of recombinant human interleukin-3 in patients with bone marrow failure. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] E. Estey,et al. Differential dose‐related haematological effects of GM‐CSF in pancytopenia: evidence supporting the advantage of low‐ over high‐dose administration in selected patients , 1991, British journal of haematology.
[27] P. Greenberg,et al. Effects of CSFs in preleukemia. , 1990, Bone marrow transplantation.
[28] J. Sklar,et al. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor. , 1990, Blood.
[29] M. Boogaerts,et al. Recombinant human erythropoietin for the treatment of anemia in the myelodysplastic syndromes: A clinical and erythrokinetic assessment , 2005, Annals of Hematology.
[30] H. Chi,et al. Spontaneous remission of aplastic anemia: a retrospective analysis. , 2001, Haematologica.
[31] M. Brereton,et al. Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors. , 2000, British journal of haematology.
[32] V. Santini,et al. Amifostine in the treatment of low-risk myelodysplastic syndromes. , 2000, Haematologica.
[33] J. Vose,et al. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation. , 2000, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[34] M. Gordon. Advances in supportive care of myelodysplastic syndromes. , 1999, Seminars in hematology.
[35] Yoshiyuki Kobayashi,et al. Trilineage recovery by combination therapy with recombinant human granulocyte colony‐stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia , 1994, Stem cells.
[36] G Barosi,et al. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. , 1992, Blood.
[37] H. Gerhartz,et al. A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. , 1992, Annals of hematology.
[38] E. Estey,et al. Erythropoietin treatment in patients with myelodysplastic syndrome and anemia. , 1991, Leukemia.
[39] I. Jinnai,et al. Improvement of anemia by recombinant erythropoietin in patients with myelodysplastic syndromes and aplastic anemia. , 1990, International journal of cell cloning.